GlassScriptPhysician profile
Blaine C Britt
NPI 1255593265
$6,616.61
in general payments reported to CMS, 2019-2025
38 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $1,346 · 2021: $681 · 2022: $389 · 2023: $1,187 · 2024: $1,189 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,769.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,158.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $753.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $413.77 | 2020-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.09 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $220.12 | 2023-2025 | |
| Abbvie INC. | $177.81 | 2021-2025 | Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $176.98 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $164.59 | 2019-2025 | Otezla, Repatha, Repatha |
| Viiv Healthcare Company | $155.42 | 2020 | |
| Supernus Pharmaceuticals, INC. | $145.60 | 2021-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $132.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.09 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $106.08 | 2019-2024 | |
| Mylan Specialty L.P. | $99.03 | 2022-2024 | Yupelri |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaine Britt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.